drugset / Trial / NCT00192842

Gemcitabine With Curcumin for Pancreatic Cancer

NCT00192842

Phase 2 Completed 17 enrolled Rambam Health Care Campus
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Timeline

Start
2004-07
Primary completion
2007-11
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 8 g Oral
Background Gemcitabine Small molecule